GC
SAGE

Grace Capital’s Sage Therapeutics SAGE Stock Holding History

Grace Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,000
Closed -$192K – 219
2018
Q4 		$192K Sell
2,000
-2,837
-59% -$325K 0.09% 162
2018
Q3 		$683K Hold
4,837
– – 0.27% 83
2018
Q2 		$757K Buy
+4,837
New +$759K 0.29% 90

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Grace Capital's SAGE Position: Q1 2019 in Review

Grace Capital sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 2,000 shares — an estimated $192K sold.

Grace Capital first reported a position in SAGE in Q2 2018 and held it in 3 quarters. The position peaked at $757K in Q2 2018. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • Grace Capital reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Grace Capital sold 2,000 Sage Therapeutics shares in Q1 2019, an estimated $192K.
  • Grace Capital first reported a position in Sage Therapeutics in Q2 2018 and held it in 3 quarters.
  • Grace Capital's Sage Therapeutics position peaked at $757K in Q2 2018.
  • 268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Grace Capital's 13F filing for Q1 2019, filed 15 May 2019.